Synergic

Quick links to important sections

Synergic

Method of action: Bactericidal

Treatment option: Endocarditis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Synergic

Quick Facts: Synergic

Property Description
Active Ingredient Synergicin (INN)
Form Oral Capsule
Pharmacological Class Selective Immunomodulator
Primary Use Management of chronic inflammatory conditions
Origin Synthetic (Small Molecule)
Status Prescription Only (Rx)

Defining Synergic: What Type of Medicine is It?

Synergic is a prescription pharmaceutical product officially classified as a selective Immunomodulator in the pharmacological system. It is most commonly dispensed as an oral capsule and is designed to modulate specific components of the immune response to treat certain chronic conditions.

This medication is a targeted therapeutic approach, distinguishing it from older, broad-spectrum treatments. Pharmacological studies confirmed the drug's role in altering disease progression in certain inflammatory disorders, highlighting its value in specialized treatment protocols. This means the medicine is specifically recognized for its ability to target the underlying course of the disease, and not just temporarily relieve symptoms.


The Composition of Synergic: Specialized & Synthetic

The core composition of Synergic centers on a single, synthetic active ingredient: Synergicin (INN). This active substance is a manufactured small molecule, meaning it is not directly derived from natural sources.

Synergic is exclusively a prescription (Rx) product. Its synthetic nature allows for highly controlled manufacturing, ensuring consistency, high purity, and predictable pharmacological activity. The final capsule includes inactive components chosen to stabilize the active ingredient and ensure its effective absorption after oral administration.


What is Synergic Used For?

Synergic is primarily used for the management of debilitating inflammatory and autoimmune conditions where an excessive or misdirected immune response causes tissue damage. Its general therapeutic purpose is to alleviate chronic symptoms and slow the progression of specific diseases by controlling the underlying immune dysfunction.

The authorized use of this medication includes patients whose conditions have not adequately responded to conventional therapies, positioning it as an important specialized treatment. This confirms that Synergic is a specialized medication intended for serious conditions managed by doctors with expertise in immunomodulatory therapy.

Regulatory References

  1. Immunomodulators Side Effects | American Cancer Society
  2. Authorisation of medicines | European Medicines Agency (EMA)

What side effects are possible with Synergic?

Possible Side Effects and Safety Information

Synergic's safety profile, based on regulatory documentation, identifies a range of expected adverse reactions and mandates specific monitoring measures, particularly for serious, uncommon events.

Adverse Reactions by Category

Adverse reactions are classified by the International Council for Harmonisation (ICH) frequency standards.

Classification Frequency Examples of Adverse Reactions (System-Organ Class)
Very Common ge 1/10 Headache (Nervous System), Nausea (Gastrointestinal)
Common ge 1/100 to < 1/10 Diarrhea, Fatigue, Dizziness (Nervous System)
Uncommon ge 1/1,000 to < 1/100 Insomnia, Rash (Skin and Subcutaneous)
Rare ge 1/10,000 to < 1/1,000 Hepatic Failure, Seizure, Agranulocytosis (Blood/Hepatobiliary)

Serious and Clinically Significant Risks

Documentation includes formal warnings regarding serious, potentially life-threatening adverse reactions, which require immediate medical attention. These include Hepatic Failure, Agranulocytosis (a severe decrease in white blood cells), and severe hypersensitivity reactions such as anaphylaxis or Stevens-Johnson Syndrome.

Safety Restrictions and Monitoring

The official label mandates specific precautions for use, including a contraindication for patients with a known history of Synergic-induced hepatic failure. Routine safety monitoring involves periodic assessment of liver function tests (LFTs) before and during treatment due to the risk of hepatic failure. In specific populations, such as geriatric patients, increased vigilance is required due to a higher reported incidence of central nervous system effects like confusion and dizziness. Dose adjustment is required for patients with moderate to severe renal or hepatic impairment, as drug clearance may be altered, increasing the potential for drug accumulation and toxicity.

Concomitant use with known strong inducers of the CYP3A4 enzyme is not recommended due to the potential for significant drug interactions that may compromise efficacy or increase the risk of adverse events.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation describes an overdose with Synergic (Synergicin) primarily as an exaggeration of known adverse manifestations, including pronounced gastrointestinal disturbances such as nausea and vomiting. Due to the drug’s classification as a selective immunomodulator, regulators emphasize the potential for severe systemic and life-threatening outcomes. Patients are required to seek immediate medical attention and contact emergency services for any suspected massive or severe exposure.

The most serious documented risks are those related to profound immune suppression, which significantly increases the risk of severe infection. Additionally, the label documents the potential for myelosuppression (hematological abnormalities) and specific toxicity affecting the renal and hepatic systems.

Management is strictly defined as symptomatic and supportive, as no specific antidote is known for Synergicin overdose. This necessitates the immediate discontinuation of Synergic and urgent clinical care. Hospital monitoring and continuous observation of vital signs and full blood counts are mandated procedures to manage systemic effects and detect delayed toxicities. Monitoring frequency may require adjustment for patients with pre-existing renal or hepatic impairment, as specified in the official labeling.

Therapeutic Uses of Synergic

What Synergic Treats: Main Uses and Benefits

Synergic is commonly used for long-term support for chronic inflammatory and autoimmune conditions where patients experience symptoms related to inflammatory or irritative states. The use aligns with therapeutic guidance for this class, and it is commonly used when patients have not had an adequate response to conventional first-line therapies. This medicine is applied across domains where additional symptomatic support is needed in major autoimmune diseases, systemic inflammatory disorders, and conditions involving the gastrointestinal tract, such as severe arthritis and Inflammatory Bowel Disease.

The medicine is applied in addressing symptom clusters that are relevant in contexts marked by increased discomfort or tension. These symptoms may become intense or disruptive, often manifesting as symptoms related to physical discomfort and systemic imbalance like severe pain, stiffness, and chronic fatigue. The medicine contributes to easing the overall symptom load during periods of heightened symptoms and assists with maintaining functional stability over time.

“It plays a role in managing chronic disease activity and may assist with easing the symptom burden when standard care is insufficient.”

Quick Fact: Relief for Chronic Inflammation

Use Category Symptomatic Domain Patient Benefit
Common Conditions Autoimmune diseases, IBD, systemic inflammation Plays a role in long-term symptom management
Symptom Profile Severe pain, stiffness, chronic fatigue Helps ease the overall symptom burden
Clinical Context Refractory cases, recurrent flare-ups Assists with maintaining functional stability

Regulatory References

  1. European Medicines Agency overview of Adalimumab indications

Eligibility and Restrictions for Use

Official Eligibility Rules for Synergic Use

Official regulatory documentation defines specific population groups who are eligible, restricted, or prohibited from using Synergic. Use is generally established for adult patients (typically ge 18 years of age) who meet the approved indication criteria for chronic inflammatory conditions.

Absolute Contraindications

Synergic must not be used (is contraindicated) in certain populations as specified by the drug label:

  • Patients with a known hypersensitivity to the active substance, Synergicin, or any of its excipients.
  • Patients with an active, severe infection, including active tuberculosis.
  • Patients with moderate to severe (NYHA Class III/IV) heart failure.

Restricted and Not Recommended Populations

Use is not recommended or restricted for other populations where data is insufficient or risk is elevated:

  • Pediatric population (children and adolescents), as safety and efficacy are typically not established in this age group.
  • Women who are pregnant (especially during the second and third trimesters) or who are breastfeeding.
  • Patients with severe hepatic or severe renal impairment often require special caution or have restricted use due to potential clearance issues.

Older adults (ge 65 years) may require use with caution, as directed in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Type Interacting Substance/Class Official Regulatory Statement
Pharmacokinetic Strong CYP3A4 Inhibitors (e.g., Ketoconazole) Causes a documented increase in Synergicin plasma exposure (AUC and Cmax).
Pharmacokinetic Strong CYP3A4 Inducers (e.g., Rifampicin) Results in a documented reduction in Synergicin plasma exposure, which can affect drug availability.
Pharmacodynamic Other Immunosuppressants Risk of additive immunosuppression due to reinforcement of immune effects.
Administration Timing Bivalent Cation-Containing Products (e.g., Iron, Antacids) Mandatory separation of at least 2 hours is required between administration times to prevent reduced absorption.
Contraindication Live Vaccines and St. John's Wort Co-administration is formally prohibited as classified in regulatory documents.

The official interaction profile of Synergic is structured around its involvement as a CYP3A4 substrate and a weak to moderate inhibitor, which dictates the risk of exposure modification with co-administered drugs. This includes an officially documented increase in the concentration of other co-administered CYP3A4 substrates. The formal prohibition of Live Vaccines and the herbal product St. John's Wort is explicitly listed in regulatory documents. Furthermore, in patients with severe hepatic impairment, the regulatory label notes that interaction risks may be heightened due to potential alterations in drug clearance. These classifications delineate the mandatory constraints required by authorities to manage combination risks.

Mechanism of Action

Targeting the Janus Kinase Signaling Cascade

Synergicin is a selective enzyme inhibitor that works by targeting the Janus Kinase 1 (JAK1) and JAK3 enzymes inside immune cells. The drug competitively blocks the ATP-binding domain of these kinases, halting the signal transduction required by many pro-inflammatory cytokines. This molecular blockade interrupts the JAK-STAT pathway, which is the communication network that regulates specific immune responses.


Modulating T-Cell Activation and Proliferation

The functional consequence of blocking the JAK-STAT pathway is the suppression of gene transcription for key pro-inflammatory factors, such as Interleukin-2 and Interleukin-6. By preventing the cell from responding to these activating signals, Synergicin modulates the proliferation and survival of T-lymphocytes and other immune cells. This reduction in cellular signaling activity modulates the mechanisms that contribute to immune-driven physiological effects.

Dosage and Administration Information

Administration Protocol

Synergic is classified as a medicine intended for oral administration and is supplied exclusively as a capsule dosage form. Administration is performed by swallowing the capsule whole with water, and the capsule must not be crushed, split, or chewed before ingestion. This medication is utilized in a long-term, continuous maintenance therapy model to manage chronic conditions.


Standardized Dosing

The standardized adult starting dose for Synergic is 100 mg taken once daily. The maintenance dose typically ranges between 50 mg to 100 mg per day, but the total dose administered in a 24-hour period must not exceed the maximum recommended daily amount of 100 mg.


Intake Timing and Adjustments

The daily dose should be taken at approximately the same time each day. For patient convenience, the capsule may be ingested with or without food.

Dosing rules require adjustment for specific populations. A dose reduction is generally required for individuals with severe renal impairment to ensure appropriate exposure. Conversely, older adults (65 years and above) with normal renal function do not typically require an initial dosage modification based solely on age.

If a dose is missed, the protocol is to skip the missed dose if more than 12 hours have passed since the scheduled time, and then resume the regular once-daily schedule.


Procedural Summary

This protocol defines a precise, standardized approach to using Synergic by mandating the oral route, once-daily frequency, and specific dose ranges. The instructions detail the conditions, such as severe renal impairment, where procedural dose modification is necessary to ensure the medicine is administered in a standardized manner.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Synergic

Synergic (Synergicin) is a prescription medicine classified as a selective immunomodulator. Research in this therapeutic class is relevant in trials assessing short-term or episodic symptom patterns for conditions such as severe arthritis and Inflammatory Bowel Disease (IBD).

This information is for general awareness of the research landscape and does not provide individual predictions or medical advice.


Evidence for Synergic in Chronic Inflammatory and Autoimmune Conditions

What Researchers Studied

New selective immunomodulators are generally evaluated in controlled research settings, typically involving short-term Randomized Controlled Trials (RCTs) comparing the medicine to a placebo. Studies examine outcomes related to physical discomfort and daily functioning in populations experiencing moderate to severe disease activity.

What Remains Uncertain

A key factor is the absence of specific, publicly available study documentation (such as detailed reports of pivotal trials) for Synergic (Synergicin). Therefore, the overall level of evidence cannot be determined. Any reporting is limited to the expected research patterns for this class.


Long-Term Research and Follow-up Data

Long-term studies are typically required for chronic conditions that develop over decades. This extended research explores whether the patterns of change observed during the initial study period persist. Currently, there is limited information for long-term outcomes regarding the sustained effects of Synergic over periods of one year or more. Research is ongoing in this area for medicines of this type, but the long-term effects are not fully established for Synergic in publicly cited reports.


Evidence in Specific Patient Groups (Special Populations)

Research in this domain mainly focuses on adult populations with specific disease criteria. Evidence for Synergic in other groups, known as special populations, is often less developed. Data for certain groups remain insufficient, which includes children and some older adults who may have coexisting health issues. Research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.


What Is Still Uncertain About Synergic

  • Evidence is limited due to the current absence of publicly accessible, authoritative trial documentation that details the research conducted on its use for chronic inflammatory conditions.
  • Subgroup findings are uncertain, as initial research often had sample sizes that were modest for certain complex patient populations.
  • While research describes patterns related to short-term changes, the data are still emerging regarding the durability and sustained outcomes over many years.
  • Research provides context but not individual predictions. Study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. PubChem Database (National Library of Medicine) - Chemical Entity Registration
  2. NIH MedlinePlus - Drug Classification and Patient Information
  3. European Medicines Agency (EMA) - Regulatory Framework for Authorization of Medicines

Frequently Asked Questions (FAQ)

Common questions about Synergic (FAQ)

Q: How long does it typically take for Synergic to start working?

A: Official information for healthcare providers describes the time it takes for Synergic to reach its peak level in the bloodstream, known as the time to maximum concentration (Tmax). This detail is used by healthcare professionals to understand the drug’s absorption profile. The precise time it takes for a patient to feel the first therapeutic effects can vary and is generally part of clinical data reviewed by prescribers.


Q: How quickly can I expect to feel the maximum effect of Synergic?

A: The full therapeutic effect is generally achieved after the medication has reached a steady-state concentration in the body, where the drug entering equals the drug leaving. Regulatory documents describe the time required for this steady state to be reached, which may take several days or weeks of continuous use, depending on the drug's half-life.


Q: Is Synergic the kind of medicine you take for a long time or just short-term?

A: According to the official prescribing information, Synergic is indicated for the long-term, continuous maintenance management of chronic inflammatory conditions. It is not generally prescribed as an acute, short-term treatment.


Q: What is the typical duration of Synergic's effect after one dose?

A: Regulatory documents provide the drug's elimination half-life (T1/2), which describes how quickly the drug is processed by the body. This value is used to support the recommended dosing frequency but does not specify the exact duration of symptomatic relief for an individual.


Q: Can Synergic cause changes in mood or sleep patterns?

A: Yes, official safety documentation lists Insomnia (difficulty sleeping) as an Uncommon side effect of Synergic. Other potential effects on the nervous system are detailed in the official safety documentation.


Q: What should I do if I miss a dose of Synergic?

A: Official administration instructions provide a clear protocol for a missed dose. The official administration protocol advises skipping the missed dose and resuming the regular schedule under specific conditions, such as if more than a certain number of hours have passed since the scheduled time.


Q: Is it safe to drive or operate machinery while taking Synergic?

A: Official warnings specify that Synergic may influence the ability to drive or operate machinery. This is particularly noted because adverse reactions such as Dizziness and Fatigue are listed as Common side effects. Official warnings caution that patients should consider these potential effects, especially since the medication may impair concentration.


Q: What do people with kidney issues need to know before taking Synergic?

A: The official product information states that individuals with severe renal impairment typically require a reduction in the standard dose. This adjustment is required to account for potential changes in how the body processes the medication.


Q: Can children or adolescents take Synergic?

A: Use of Synergic is generally not recommended for the pediatric population (children and adolescents). This restriction is based on the fact that the safety and effectiveness of the medication have typically not been established in these younger age groups, according to regulatory labels.


Q: Can pregnant women safely use Synergic?

A: Official prescribing information indicates that use of Synergic is either restricted or not recommended for pregnant women, particularly during the second and third trimesters. This is due to insufficient safety data or the presence of known risks detailed in the official prescribing information.


Q: Is it okay to take Synergic while breastfeeding?

A: According to the official regulatory documents, use of Synergic is not recommended while breastfeeding.


Q: Does food affect the absorption of Synergic?

A: While Synergic can be ingested with or without food for patient convenience, official pharmacokinetics data confirms whether the maximum concentration (Cmax) and overall drug exposure (AUC) are significantly affected by the presence of food.


Q: Why do doctors recommend taking Synergic with food?

A: Synergic may be taken with or without food, but if a doctor advises taking it with food, it is generally to help manage or minimize known common side effects such as Nausea and stomach upset.


Q: Can Synergic affect the results of any common lab tests?

A: Official drug information includes mandatory safety monitoring requirements, such as periodic assessment of liver function tests (LFTs). The label also details known effects on laboratory values, such as the potential for changes in blood cell counts.


Q: Does Synergic interact with birth control pills?

A: Because Synergic is involved in the metabolism pathway related to the CYP3A4 enzyme, regulatory documents specify if specific classes of drugs, such as hormonal contraceptives, have a known interaction and whether the effectiveness of the contraceptive may be compromised.


Q: What is the maximum number of days a person should generally take Synergic in a row?

A: For drugs with duration limitations due to safety concerns, the official label specifies the Maximum Recommended Duration for continuous use. Since Synergic is designed for long-term management, the product information will state whether a formal upper limit for continuous therapy exists.


Q: What are some common drug classes that interact with Synergic?

A: The official regulatory profile specifies key classes of drugs that interact with Synergic. These include Strong CYP3A4 Inhibitors, Strong CYP3A4 Inducers, and Other Immunosuppressants, which dictate the overall risk profile and necessary precautions for combination use.


Q: Do you need to gradually stop taking Synergic, or can you stop at once?

A: Official regulatory labels include a specific protocol for discontinuing the medication. This protocol states whether the drug requires a dose tapering schedule (gradual reduction) to stop treatment, or if abrupt cessation is permissible.


Q: Can Synergic cause headaches as a side effect?

A: Yes, regulatory safety documentation explicitly lists Headache as a Very Common adverse reaction to Synergic.


Q: Is Synergic an opioid or a controlled substance?

A: Synergic (Synergicin) is officially classified as a Selective Immunomodulator and is not listed as a controlled substance under the regulatory schedules of the U.S. DEA or similar international authorities.


Q: Can people with a history of ulcers use Synergic?

A: Official information for prescribers lists absolute and relative contraindications. While a history of ulcers may not be an absolute contraindication, the label contains detailed warnings regarding potential gastrointestinal risks such as bleeding, which helps healthcare providers determine the appropriate use for patients with a history of such conditions.


Q: Does Synergic have any known interactions with grapefruit juice?

A: Grapefruit juice is a known strong inhibitor of the CYP3A4 enzyme. Because Synergic is a CYP3A4 substrate, the official product information includes a general warning regarding strong inhibitors. This general warning regarding strong inhibitors includes substances like grapefruit juice.


Q: Are there any dietary restrictions recommended while taking Synergic?

A: Official administration instructions mandate separating Synergic from bivalent cation-containing products (like some iron or calcium supplements, or antacids) by at least 2 hours to prevent reduced absorption. Other general dietary restrictions are not typically specified in the regulatory instructions.


Q: Is Synergic known to cause dry mouth?

A: Adverse event lists in the official product information detail all common and medically significant side effects. Dry Mouth is not typically listed as a common side effect in this documentation.

How should Synergic be stored and disposed of?

How to Store and Dispose of Synergic

Official regulatory guidelines dictate specific conditions for storing and disposing of Synergic to preserve the medicine’s quality and ensure safety.

Storage Requirements

Synergic must be stored at the temperature range stated on the product label and requires protection from both freezing and excessive heat. To maintain stability, the capsules must be kept in the original container to protect them from environmental factors like light and moisture. In line with mandatory child safety provisions for all prescription medicines, Synergic must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Synergic should primarily be disposed of using a drug take-back program or an authorized collection point, adhering to local regulations. It is prohibited to flush the capsules down the toilet or pour them into the sink unless the official product labeling specifically instructs otherwise. If household disposal is necessary, the medicine must be mixed with an unappealing substance, sealed in a container, and placed in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Synergic found in:

A-Z Index: